Private sector delivery opportunities for the Dual Prevention Pill: Lessons from Family Planning for the introduction of Multi-purpose Prevention Technologies

Wednesday12October

Virtual

Please join AVAC and FP2030 for a webinar on the DPP, a daily pill that is currently being developed for simultaneous pregnancy and HIV prevention. This webinar will highlight new findings on private sector opportunities for the DPP in Kenya, South Africa and Zimbabwe. It will explore lessons and successes from the FP experience to identify how FP/SRH stakeholders can help pave the way for smooth introduction of MPTs like the DPP in private sector channels.

Agenda

Welcome and objectives
What FP stakeholders want to know about the DPP: Questions and issues raised in the April 2022 DPP consultation
Opportunities for the DPP in the private sector: Findings from Kenya, South Africa, and Zimbabwe
Lessons from country level: Best practices for FP introduction in the private sector
Innovations in service delivery: The future of direct-to-consumer care and implications for product introduction
Panel/Q&A
Closing remarks: Key takeaways and opportunities for continued engagement

Featured Resources

External Link

How Might We Motivate Uptake of the Dual Prevention Pill? Findings from human-centered design research with potential end users, male partners, and healthcare providers

This article from Frontiers in Reproductive Health describes the results of a study to identify barriers and motivators for Dual Prevention Pill (DPP) uptake to inform the development of a DPP demand generation strategy and broader introduction efforts for Multipurpose Prevention Technologies.

Document

Rapid Landscape Analysis of National Vertical Transmission Policies for Inclusion of PrEP for Pregnant and Breastfeeding People

Elimination of vertical transmission of HIV will require expanded access to HIV prevention strategies, such as PrEP, for pregnant and breastfeeding people. Guidance from the World Health Organization (WHO) supports provision of HIV pre-exposure prophylaxis (PrEP) to pregnant and breastfeeding people (PBFP) who are at continuing substantial risk of HIV infection. Evidence has shown that…

Document

Dual Prevention Pill: Market Preparation and Introduction Strategy

This strategy, updated in August 2023, is intended for donors, governments, implementing partners and civil society to inform priorities and planning for DPP rollout. The strategy describes activities required to build a cohesive body of evidence and recommends an approach to DPP introduction to focus efforts. Where possible, activities will be embedded into existing programs…

External Link

Integrated Study Dashboard

This dashboard, produced under the BioPIC project, reflects all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new late stage biomedical HIV PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring. To update or add any activities missing from the dashboard, or if you have questions on using…

External Link

Cost-Effectiveness of the Dual Prevention Pill for Contraception and HIV Pre-Exposure Prophylaxis

This journal article from Frontiers in Reproductive Health explored what populations and in what use cases the DPP (dual prevention pill) would be cost-effective.

External Link

Equipping Providers To Offer Novel MPTs: Developing Counseling Messages for the Dual Prevention Pill in Clinical Studies and Beyond

This journal article from Frontiers in Reproductive Health shares results from mapping counseling messages from COC and oral PrEP guidance and provider training materials. This was studied by a working group of eight HIV and FP experts.

Document

Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Report

This report was from the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and FP…

Presentation

Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Slides

These slides were featured at the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and…

Document

Private Sector Delivery Strategy for the Dual Prevention Pill: Kenya and Zimbabwe

This strategy was authored by the DPP Consortium to prepare for market entry of the DPP (Dual Prevention Pill) in Kenya and Zimbabwe.

External Link

Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative findings on MPT attribute preferences from the CUPID study (MTN-045)

This article from the Journal of the International AIDS Society uses data from the Microbicide Trials Network 045 study in Uganda and Zimbabwe to examine (1) how couples make decisions on existing non-Multipurpose Technology (MPT) HIV and pregnancy prevention products; (2) how couples make decisions on future ideal-MPT products; and (3) how these decision-making processes…